Non-clinical Pharmacology of YTX-7739: a Clinical Stage Stearoyl-CoA Desaturase Inhibitor Being Developed for Parkinson’s Disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1559-1182
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Non-clinical Pharmacology of YTX-7739: a Clinical Stage Stearoyl-CoA Desaturase Inhibitor Being Developed for Parkinson’s Disease ; volume:59 ; number:4 ; day:20 ; month:1 ; year:2022 ; pages:2171-2189 ; date:4.2022
Molecular neurobiology ; 59, Heft 4 (20.1.2022), 2171-2189, 4.2022
- Creator
-
Tardiff, Daniel F.
Lucas, Matthew
Wrona, Iwona
Chang, Belle
Chung, Chee Yeun
Bourdonnec, Bertrand Le
Rhodes, Kenneth J.
Scannevin, Robert H.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12035-021-02695-1
- URN
-
urn:nbn:de:101:1-2022070207275291959371
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tardiff, Daniel F.
- Lucas, Matthew
- Wrona, Iwona
- Chang, Belle
- Chung, Chee Yeun
- Bourdonnec, Bertrand Le
- Rhodes, Kenneth J.
- Scannevin, Robert H.
- SpringerLink (Online service)
Other Objects (12)
Predicting cognitive decline with non-clinical markers in Parkinson’s disease (PRECODE-2)
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
Clinical Criteria for the Diagnosis of Parkinson’s Disease
Genetic testing for Parkinson’s disease in clinical practice
Clinical pharmacology
Landscape of pain in Parkinson’s disease : impact of gender and Parkinson’s disease clinical phenotype
The clinical diagnosis of Parkinson's disease
Constipation and pain in Parkinson’s disease: a clinical analysis
Clinical aspects of palliative care in advanced Parkinson’s disease
Gut microbiota helps identify clinical subtypes of Parkinson’s disease
Cerebro-cerebellar motor networks in clinical subtypes of Parkinson’s disease
Mild cognitive impairment in Parkinson’s disease: a distinct clinical entity?
Predicting cognitive decline with non-clinical markers in Parkinson’s disease (PRECODE-2)
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
Clinical Criteria for the Diagnosis of Parkinson’s Disease
Genetic testing for Parkinson’s disease in clinical practice
Clinical pharmacology
Landscape of pain in Parkinson’s disease : impact of gender and Parkinson’s disease clinical phenotype
The clinical diagnosis of Parkinson's disease
Constipation and pain in Parkinson’s disease: a clinical analysis
Clinical aspects of palliative care in advanced Parkinson’s disease
Gut microbiota helps identify clinical subtypes of Parkinson’s disease
Cerebro-cerebellar motor networks in clinical subtypes of Parkinson’s disease
Mild cognitive impairment in Parkinson’s disease: a distinct clinical entity?
Predicting cognitive decline with non-clinical markers in Parkinson’s disease (PRECODE-2)
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
Clinical Criteria for the Diagnosis of Parkinson’s Disease
Genetic testing for Parkinson’s disease in clinical practice
Clinical pharmacology
Landscape of pain in Parkinson’s disease : impact of gender and Parkinson’s disease clinical phenotype
The clinical diagnosis of Parkinson's disease
Constipation and pain in Parkinson’s disease: a clinical analysis
Clinical aspects of palliative care in advanced Parkinson’s disease
Gut microbiota helps identify clinical subtypes of Parkinson’s disease
Cerebro-cerebellar motor networks in clinical subtypes of Parkinson’s disease